Podoplanin Expression Independently and Jointly with Oral Epithelial Dysplasia Grade Acts As a Potential Biomarker of Malignant Transformation in Oral Leukoplakia

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 May 28

PMID 35625534

Authors

Luis Monteiro

Barbas do Amaral

Leonor Delgado

Fernanda Garces

Filomena Salazar

Jose Julio Pacheco

Carlos Lopes

Saman Warnakulasuriya

Affiliations

Soon will be listed here.

Abstract

Our aim was to evaluate the expression of biomarkers, CD44v6, CD147, EGFR, p53, p63, p73, p16, and podoplanin in oral leukoplakias (OL) and to assess their potential for prediction of malignant transformation (MT). We analyzed the expression of CD44v6, CD147, EGFR, p53, p63, p73, p16, and podoplanin by immunohistochemistry in 52 OL, comprised of 41 low-grade (LG) dysplasia and 11 high-grade (HG) cases. Twelve healthy normal tissues (NT) were also included. Univariate and multivariate analysis were performed to evaluate any association with MT. Variable expression among the studied markers was observed, with a significant increase of high expression from NT to LG and HG cases in CD44v6 (p = 0.002), P53 (p = 0.002), P73 (p = 0.043), and podoplanin (p < 0.001). In multivariate analysis, cases with high podoplanin score showed a significant increased risk of MT (HR of 10.148 (95% CI of 1.503−68.532; p = 0.017). Furthermore, podoplanin combined with binary dysplasia grade obtained a HR of 10.238 (95% CI of 2.06−50.889; p = 0.004). To conclude, CD44v6, p53, p73, and podoplanin showed an increasing expression along the natural history of oral carcinogenesis. Podoplanin expression independently or combined with dysplasia grade could be useful predictive markers of MT in OL.

Citing Articles

Potential Immunohistochemical Biomarkers for Grading Oral Dysplasia: A Literature Review.

Zdrojewski J, Nowak M, Nijakowski K, Jankowski J, Scribante A, Gallo S Biomedicines. 2024; 12(3).

PMID: 38540190 PMC: 10967812. DOI: 10.3390/biomedicines12030577.

Biomarkers of malignant transformation in oral leukoplakia: from bench to bedside.

Cai X, Zhang J, Zhang H, Li T J Zhejiang Univ Sci B. 2023; 24(10):868-882.

PMID: 37752089 PMC: 10522567. DOI: 10.1631/jzus.B2200589.

Role of Ceramide Synthase 1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Potential Linchpin for Tumorigenesis.

Surendran S, Krishnan R, Ramani P, Ramalingam K, Jayaraman S Cureus. 2023; 15(7):e42308.

PMID: 37614280 PMC: 10442516. DOI: 10.7759/cureus.42308.

References

Chai A, Lim K, Cheong S . Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2019; 61:71-83. DOI: 10.1016/j.semcancer.2019.09.011. View

Dionne K, Warnakulasuriya S, Zain R, Cheong S . Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory. Int J Cancer. 2014; 136(3):503-15. DOI: 10.1002/ijc.28754. View

Speight P, Khurram S, Kujan O . Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018; 125(6):612-627. DOI: 10.1016/j.oooo.2017.12.011. View

Saintigny P, El-Naggar A, Papadimitrakopoulou V, Ren H, Fan Y, Feng L . DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009; 15(19):6284-91. PMC: 2756317. DOI: 10.1158/1078-0432.CCR-09-0498. View

Saluja T, Ali M, Mishra P, Kumar V, Singh S . Prognostic Value of Cancer Stem Cell Markers in Potentially Malignant Disorders of Oral Mucosa: A Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2018; 28(1):144-153. DOI: 10.1158/1055-9965.EPI-18-0672. View

Gissi D, Gabusi A, Tarsitano A, Luccarini L, Morandi L, Montebugnoli L . Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia. J Craniomaxillofac Surg. 2018; 46(5):759-764. DOI: 10.1016/j.jcms.2018.02.016. View

Monteiro L, Mello F, Warnakulasuriya S . Tissue biomarkers for predicting the risk of oral cancer in patients diagnosed with oral leukoplakia: A systematic review. Oral Dis. 2020; 27(8):1977-1992. DOI: 10.1111/odi.13747. View

Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y . Podoplanin promotes cell migration via the EGF-Src-Cas pathway in oral squamous cell carcinoma cell lines. J Oral Sci. 2012; 54(3):241-50. DOI: 10.2334/josnusd.54.241. View

Celentano A, Glurich I, Borgnakke W, Farah C . World Workshop on Oral Medicine VII: Prognostic biomarkers in oral leukoplakia and proliferative verrucous leukoplakia-A systematic review of retrospective studies. Oral Dis. 2020; 27(4):848-880. DOI: 10.1111/odi.13363. View

10.

Rosin M, Cheng X, Poh C, Lam W, Huang Y, Lovas J . Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000; 6(2):357-62. View

11.

Villa A, Celentano A, Glurich I, Borgnakke W, Jensen S, Peterson D . World Workshop on Oral Medicine VII: Prognostic biomarkers in oral leukoplakia: A systematic review of longitudinal studies. Oral Dis. 2019; 25 Suppl 1:64-78. PMC: 6544170. DOI: 10.1111/odi.13087. View

12.

Lydiatt W, Patel S, OSullivan B, Brandwein M, Ridge J, Migliacci J . Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(2):122-137. DOI: 10.3322/caac.21389. View

13.

Grochau K, Safi A, Drebber U, Grandoch A, Zoller J, Kreppel M . Podoplanin expression in oral leukoplakia─a prospective study. J Craniomaxillofac Surg. 2019; 47(3):505-509. DOI: 10.1016/j.jcms.2018.12.005. View

14.

Warnakulasuriya S, Kovacevic T, Madden P, Coupland V, Sperandio M, Odell E . Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England. J Oral Pathol Med. 2011; 40(9):677-83. DOI: 10.1111/j.1600-0714.2011.01054.x. View

15.

Sundberg J, Pandey S, Giglio D, Holmberg E, Kjeller G, Kovacs A . Expression of p53, p63, podoplanin and Ki-67 in recurring versus non-recurring oral leukoplakia. Sci Rep. 2021; 11(1):20781. PMC: 8531318. DOI: 10.1038/s41598-021-99326-5. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Speight P, Abram T, Floriano P, James R, Vick J, Thornhill M . Interobserver agreement in dysplasia grading: toward an enhanced gold standard for clinical pathology trials. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120(4):474-82.e2. PMC: 4564355. DOI: 10.1016/j.oooo.2015.05.023. View

18.

El-Naggar A, Lai S, Clayman G, Mims B, Lippman S, Coombes M . p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 2001; 22(5):729-35. DOI: 10.1093/carcin/22.5.729. View

19.

Monteiro L, Delgado M, Ricardo S, do Amaral B, Salazar F, Pacheco J . Prognostic significance of CD44v6, p63, podoplanin and MMP-9 in oral squamous cell carcinomas. Oral Dis. 2016; 22(4):303-12. DOI: 10.1111/odi.12442. View

20.

Suwasini S, Chatterjee K, Purkait S, Samaddar D, Chatterjee A, Kumar M . Expression of P53 Protein and Ki-67 Antigen in Oral Leukoplakia with Different Histopathological Grades of Epithelial Dysplasia. J Int Soc Prev Community Dent. 2019; 8(6):513-522. PMC: 6280575. DOI: 10.4103/jispcd.JISPCD_241_18. View